Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage

As Wall Street digests a fresh Federal Reserve rate cut and growing worries about an AI spending bubble, today’s U.S. stock tape is dominated by dramatic downside moves. From Oracle’s double‑digit plunge to biotech blow‑ups and reverse‑split micro‑caps, December 11, 2025 is one of the ugliest “losers lists” investors have seen this year.

Below is a news‑driven breakdown of what’s happening, why these stocks are sinking, and what the day’s biggest losers say about the broader U.S. market.

Key takeaways

Oracle (ORCL) is down about 13% intraday, erasing tens of billions in market value after a revenue miss and a huge jump in AI data‑center spending revived “AI bubble” fears and knocked the Nasdaq lower. ^[1]
On a percentage basis, the day’s biggest losers are mainly small‑cap and micro‑cap names such as Rezolute (RZLT), C3is (CISS), Oriental Culture (OCG), GRI Bio (GRI) and MingZhu Logistics (YGMZ), with falls ranging from roughly 50% to nearly 90%. ^[2]
Many collapses are tied to clinical trial failures, dilutive equity offerings, reverse stock splits or delisting notices, not broad macro weakness. ^[3]
Consumer and retail names such as Vera Bradley (VRA) and Oxford Industries (OXM) are also on the losers board after disappointing earnings and cautious outlooks. ^[4]
At the index level, the Dow is hitting record territory, while the Nasdaq 100 trades lower, underscoring a rotation away from richly‑valued tech and speculative growth. ^[5]

Market snapshot: Fed cut meets AI hangover

According to StockAnalysis.com’s “Losers Today” dashboard, as of the latest update on December 11, 2025, the S&P 500 is down only about 0.1%, the Nasdaq 100 is off roughly 0.8%, while the Dow Jones Industrial Average is up around 1.3%, flirting with record highs. ^[6]

The backdrop:

The Federal Reserve cut rates by 25 basis points yesterday to a 3.5%–3.75% target range, its third cut of 2025, but signaled a higher bar for further easing next year. ^[7]
Today, Oracle’s earnings disappointment and aggressive AI capex plans have become the focal point, dragging tech indices lower and reigniting debate over whether AI spending has run ahead of fundamentals. ^[8]
Even Bitcoin has slipped back below $90,000, with Reuters and other outlets explicitly linking the crypto pullback to AI‑related jitters and post‑Fed risk aversion. ^[9]

In other words, macro conditions are supportive but nervous: money is getting cheaper, yet investors are suddenly more picky about where they’re willing to tolerate risk.

Today’s top U.S. stock losers by percentage

From StockAnalysis.com’s live U.S. losers list (regular U.S. exchanges only), the top 10 intraday percentage declinersas of this writing are: ^[10]

Rezolute (RZLT) – down ~88%
C3is (CISS) – down ~81%
Oriental Culture Holding (OCG) – down ~74%
GRI Bio (GRI) – down ~55%
MingZhu Logistics (YGMZ) – down ~54%
Beasley Broadcast Group (BBGI) – down ~41%
Clearmind Medicine (CMND) – down ~36%
A SPAC III Acquisition (ASPC) – down ~35%
ChowChow Cloud International (CHOW) – down ~32%
Nuvve Holding (NVVE) – down ~31%

Rounding out the top 20 are Pomdoctor (POM), Harrison Global (BLMZ), Inspire Veterinary Partners (IVP), XOMA Royalty (XOMA), Skillsoft (SKIL), Pineapple Financial (PAPL), SRx Health Solutions (SRXH), Vera Bradley (VRA), Falcon’s Beyond Global (FBYD) and Oxford Industries (OXM), all with losses of roughly 20–30%. ^[11]

Most of these are small‑cap or micro‑cap stocks—but the drama is not confined to tiny names, as Oracle’s steep slide shows.

Oracle (ORCL): AI spending shock hits a mega‑cap

Move today: Oracle shares are down roughly 13%, trading around $194 intraday and on pace for one of their worst single sessions in years. ^[12]

What went wrong in Oracle’s quarter?

Oracle’s latest fiscal Q2 report delivered a combination that markets hate:

Revenue missed Wall Street expectations, with growth in its cloud–infrastructure business not quite offsetting softness elsewhere. ^[13]
Management signaled an additional ~$15 billion in AI‑related data‑center spending on top of already‑massive capex plans, pushing expected total capex toward $50 billion. ^[14]
Forecasts and commentary left investors questioning how quickly those AI investments will translate into cash flow and earnings, especially given Oracle’s heavier reliance on debt versus peers like Microsoft or Alphabet. ^[15]

Reuters summarised the market’s verdict bluntly: Oracle’s shares sank about 13%, igniting a broader tech selloff and “fanning doubts over how quickly the big bets on AI will pay off.” ^[16]

How Wall Street is reacting

Today’s analyst notes are all over the map:

Jefferies and Mizuho both maintain bullish $400 price targets, arguing that Oracle’s AI backlog and long‑term growth opportunity still justify a premium valuation despite short‑term volatility. ^[17]
BMO Capital cut its target from $355 to $270 but kept an “Outperform” rating, calling the quarter “lackluster” on revenue but highlighting robust operating cash flow. ^[18]
Stifel trimmed its target to $275, citing concerns that capex is running ahead of demand. ^[19]
Morningstar reduced its fair‑value estimate from $340 to $286 per share after lowering its long‑term earnings outlook. ^[20]
A widely read MarketWatch column described Oracle as a “canary in the coal mine” for debt‑funded AI spending across Big Tech. ^[21]

Bottom line: Oracle remains a core player in the AI infrastructure race, but today’s price action shows that investors are no longer willing to give a free pass to debt‑heavy, capex‑first AI strategies without clear visibility on returns.

Rezolute (RZLT): late‑stage trial failure wipes out nearly 90%

Move today: Rezolute is the single biggest loser on U.S. exchanges by percentage, with shares cratering about 88% to near $1.25. ^[22]

The catalyst: failed Phase 3 “sunRIZE” study

Rezolute announced before the open that its Phase 3 sunRIZE trial of ersodetug for congenital hyperinsulinism failed to meet its primary and key secondary endpoints. ^[23]

Key points from the company and independent coverage:

The treatment group saw a 45% reduction in hypoglycemia events, but the placebo arm improved by about 40%, effectively wiping out the drug’s statistical edge. ^[24]
Rezolute was counting on this program as a flagship rare‑disease asset, so the miss raises existential questions about its pipeline and long‑term funding. ^[25]
Law firm Block & Leviton promptly announced a securities‑fraud investigation, highlighting the severity of the move and signalling potential shareholder litigation. ^[26]

Analysts covering biotech stress that after such a steep single‑day collapse, the stock effectively trades like an option on management’s ability to salvage value—for example by repurposing the drug, cutting costs, or pursuing strategic alternatives. But with the trial failure front and center, Rezolute now sits firmly in the “speculative high‑risk” bucket.

Dilution & delisting fears: C3is (CISS) and MingZhu Logistics (YGMZ)

C3is (CISS): shipping stock sinks on discounted public offering

Move today: C3is is down roughly 81%, the second‑worst decliner on major U.S. exchanges. ^[27]

The reason is straightforward and brutal:

The company announced a $9 million public offering of common stock units, with Investing.com and other outlets noting the stock plunged around 79% as traders priced in severe dilution. ^[28]

In micro‑cap shipping names, investors are acutely sensitive to equity raises at steep discounts, which can crush existing shareholders while signalling that debt or internal cash flow is not sufficient to fund growth.

MingZhu Logistics (YGMZ): Nasdaq delisting notice

Move today: MingZhu is off about 54%, putting it firmly in the top five losers. ^[29]

The company disclosed that Nasdaq will suspend trading on December 12, 2025 after MingZhu failed to regain compliance with the exchange’s $1 minimum bid requirement. ^[30]
Management plans to appeal and has floated a reverse split as part of its compliance strategy, but the stock’s collapse to just a few cents a share reflects deep skepticism about the outcome. ^[31]

These two stories exemplify a broader theme on today’s losers list: capital‑structure stress—dilutive offerings, reverse splits and delisting risks—rather than macro news—is driving many of the biggest percentage drops.

Biotech rollercoaster: GRI Bio (GRI) and Clearmind Medicine (CMND)

GRI Bio (GRI): good clinical news, ugly financing

Move today: GRI Bio is down around 55%, the fourth‑largest loser. ^[32]

The twist:

The sell‑off comes right after promising Phase IIa data for an idiopathic pulmonary fibrosis (IPF) therapy, which showed biomarker improvements and a solid safety profile. ^[33]
At the same time, GRI announced an $8 million public offering of stock and warrants, which observers say is likely the main reason for the collapse—investors fear ongoing dilution and cash‑crunch risk despite the positive science. ^[34]

This is a classic biotech paradox: strong trial data but weak balance sheet can still produce a day of brutal selling.

Clearmind Medicine (CMND): reverse split and compliance overhang

Move today: Clearmind Medicine is off about 36%, with heavy volume. ^[35]

Recent developments:

Nasdaq notified the company earlier this month that it was out of compliance with the minimum $1 bid rule. ^[36]
Today’s slide follows the announcement of a 1‑for‑40 reverse share split, effective December 15, explicitly aimed at regaining compliance. ^[37]

For traders, the combination of reverse split + tiny market cap + compliance pressure is often a red flag; many such names become short‑term trading vehicles rather than long‑term investments.

Newly listed and thinly traded tech: ChowChow Cloud (CHOW), Pomdoctor (POM), Nuvve (NVVE)

ChowChow Cloud (CHOW): post‑IPO enthusiasm unwinds

Move today: CHOW is down about 32% and sits in the top 10 losers. ^[38]

Context:

The Hong Kong–based cloud company only listed this autumn, raising roughly $12 million via its U.S. IPO. ^[39]
A TechStock² piece earlier today noted that the stock had previously spiked more than 400% above its IPO pricebefore giving back most of those gains, and that as of this morning the shares were down more than 80% from recent peaks. TechStock²+1

Today’s drop looks like another chapter in a familiar story: thinly traded post‑IPO momentum names can suffer enormous reversals once speculative interest dries up.

Pomdoctor (POM): “black swan” collapse

Move today: Pomdoctor has fallen close to 30% today alone, after suffering an intraday collapse that some analysts describe as a “black‑swan” move of around 90% from recent levels. ^[40]

A series of technical analyses on AInvest and other sites highlight:

A plunge to fresh 52‑week lows,
Massive trading volume and liquidity stress, and
Virtually no new fundamental news, suggesting the move is driven more by order‑book imbalances and speculative unwinding than by changes in operations. ^[41]

Nuvve Holding (NVVE): reverse split pain

Move today: Nuvve is down roughly 31%. ^[42]

Drivers:

The company announced a 1‑for‑40 reverse stock split, effective this week, explicitly to regain Nasdaq listing compliance. ^[43]
AInvest notes that the stock has been under pressure for months amid deep losses, high cash burn and repeated capital‑raising efforts, with today’s slide reflecting investor concern that even the reverse split may not solve underlying issues. ^[44]

Together, these names underscore the fragility of thinly traded growth stocks when financing risk and technical factors collide.

Consumer & retail pressure: Vera Bradley (VRA) and Oxford Industries (OXM)

While many of today’s extreme losers are obscure micro‑caps, a couple of consumer brands are also under heavy pressure.

Vera Bradley (VRA)

Move today: Vera Bradley is down about 22% and appears in the top‑20 losers list. ^[45]

The handbag and accessories company reported a wider‑than‑expected Q3 loss of $0.30 per share, versus analyst expectations closer to a $0.11 loss. ^[46]
Revenue of roughly $62 million was only slightly below forecasts, but the market focused on margin pressure and ongoing sales declines. ^[47]

Analyst commentary frames the stock as a turnaround story that has yet to prove it can stabilize demand and profitability in an intensely competitive apparel landscape.

Oxford Industries (OXM)

Move today: OXM, the parent of Tommy Bahama and Lilly Pulitzer, is down nearly 20%. ^[48]

The company posted a third‑quarter adjusted loss that was slightly better than forecasts, but slashed its full‑year guidance, citing tariff uncertainty and weaker consumer spending. ^[49]
Shares were already down sharply year‑to‑date, and UBS cut its price target to $35, while other research notes point to a tough 2025 outlook despite the company’s strong brand portfolio. ^[50]

These moves highlight how earnings misses and cautious forward guidance are still ruthlessly punished, even outside high‑growth tech.

What today’s biggest losers say about the U.S. market

Looking across the tape, a few themes stand out:

AI spending is under a microscope
Oracle’s drop has turned AI capex from a pure “growth story” into a capital‑allocation debate. Investors are asking whether huge, often debt‑funded AI bets can generate returns quickly enough to justify current valuations—not just for Oracle, but for much of big‑cap tech. ^[51]
Micro‑cap speculation is extremely fragile
Names like Rezolute, C3is, GRI Bio, MingZhu, Pomdoctor and ChowChow Cloud show how quickly trial outcomes, offerings, delisting notices or technical breakdowns can wipe out 50–90% of a stock’s value in a day. ^[52]
Balance sheet and listing risk matter as much as growth stories
Reverse splits (Nuvve, Clearmind), capital raises (C3is, GRI) and delisting threats (MingZhu) are recurring triggers. Today’s price action reinforces that access to capital and exchange status are crucial, especially for small caps. ^[53]
Macro is a backdrop, not the main villain
The Fed’s latest cut and a still‑resilient Dow show that broader conditions are not outright hostile—but markets are increasingly selective, rewarding quality balance sheets and punishing anything that smells of overreach or financial stress. ^[54]

How traders and investors can think about days like this

Nothing here is investment advice, but today’s action offers some practical reminders:

Check the catalyst, not just the percentage move.
A stock down 80% on a failed Phase 3 trial (Rezolute) is very different from one down 25% on a routine earnings miss. The recovery odds, timelines and risk profiles are not comparable. ^[55]
Look at capital structure and listing status.
Reverse splits, low share prices, delisting warnings and serial offerings often signal that shareholders are effectively funding survival, not growth—raising the bar for any turnaround thesis. ^[56]
Separate macro noise from company‑specific risk.
Oracle’s slide has clearly weighed on the Nasdaq, but many of today’s biggest percentage losers would likely be volatile even in a calm macro environment because of their size, liquidity and event risk. ^[57]
Use diversified research, not headlines alone.
For any stock that catches your eye, it’s worth reading the underlying press releases, SEC filings and multiple independent analyses rather than relying solely on a single headline or social‑media narrative.

Final note

All price moves and rankings described here are as of the latest available intraday data on December 11, 2025 and may change by the time you read this. Market conditions can shift rapidly—especially in the kinds of small, thinly traded stocks that dominate today’s losers list.

This article is for information and education only and is not a recommendation to buy or sell any security.

References